References 1. 이수용 기자. “2021년 식품·의약품 안전정책 이렇게 달라집니다“, 위클리오늘(2021.01.15.). Available from: http://www.weeklytoday.com/news/articleView.html?idxno=334131 2. 대한민국 정책브리핑 홈페이지 Available from: https://www.korea.kr/archive/expDocView.do?docId=39248&call_from=rsslink 3. 식품의약품안전처 식품의약품안전평가원 홈페이지 Available from: https://www.nifds.go.kr/brd/m_137/view.do?seq=32877&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 4. 식품의약품안전처 식품의약품안전평가원 홈페이지 Available from: https://www.nifds.go.kr/brd/m_15/view.do?seq=12942&srchFr=&srchTo=&srchWord=%EC%B2%A8%EB%8B%A8%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 5. 식품의약품안전처 식품의약품안전평가원 홈페이지 Available from: https://www.nifds.go.kr/brd/m_15/view.do?seq=12941&srchFr=&srchTo=&srchWord=%EC%B2%A8%EB%8B%A8%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 6. 이정수 기자. “바이오헬스 지원 완결판 ‘범부처 재생의료기술개발사업’ 부상”, 메디파나뉴스(2020.12.30.). Available from: http://medipana.com/news/news_viewer.asp?NewsNum=269142&MainKind=A&NewsKind=5&vCount=12&vKind=1 7. “Guidance Document: Human Gene Therapy for Neurodegenerative Diseases” US FDA. Last modifed Jan.5, 2021 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-neurodegenerative-diseases 8. “Guidance Document: Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products” US FDA. Last modified Dec. 16, 2020 Avaiable from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products 9. “Guidance Document: Requesting FDA Feedback on Combination Products” US FDA. Last modified Dec. 3, 2020 Avaiable from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requesting-fda-feedback-combination-products 10. “Regulatory Focus: Marks fields questions on cell and gene therapy development” RAPS. Accessed Nov. 5, 2020 Available from: https://www.raps.org/news-and-articles/news-articles/2020/11/marks-fields-questions-on-cell-and-gene-therapy-de 11. “Project Orbis: Strengthening International Collaboration for Oncology Product Reviews, Faster Patient Access to Innovative Therapies” US FDA. Accessed Dec. 8, 2020 Avaiable from: https://www.fda.gov/news-events/fda-voices/project-orbis-strengthening-international-collaboration-oncology-product-reviews-faster-patient 12. “Oncology Center of Excellence” US FDA. Last modified May. 5, 2020 Avaiable from: https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence 13. “FDA NEWS RELEASE: FDA Approves First Drug to Treat Rare Metabolic Disorder” US FDA. Accessed Nov. 23, 2020 Avaiable from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder 14. “Liver tumor in gene therapy recipient raises concerns about virus widely used in treatment” ScienceMag.org. Accessed Dec 22, 2020 Available from: https://www.sciencemag.org/news/2020/12/liver-tumor-gene-therapy-recipient-raises-concerns-about-virus-widely-used-treatment 15. “uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program” Euroland. tools. Accessed Dec 21, 2020 Available from: https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3852484&lang=en-GB&companycode=nl-qure&v= 16. “FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs” Reuters. Accessed Nov 17, 2020 Available from: https://www.reuters.com/article/us-bristol-myers-fda/fda-delays-decision-on-bristol-myers-cancer-therapy-due-to-covid-19-travel-curbs-idUSKBN27W2YW 17. “ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope” Biospace. Accessed Dec 7, 2020 Available from: https://www.biospace.com/article/ash-roundup-crispr-and-vertex-s-potential-cure-for-sickle-cell-disease-and-more/?keywords=ASH 18. “Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting” Autolus. Accessed Dec 5, 2020 Available from: http://www.globenewswire.com/news-release/2020/12/05/2140158/0/en/Autolus-Therapeuticspresents-compelling-AUTO1-data-from-ALLCAR-Phase-1-study-in-Adult-Acute-Lymphoblastic-Leukemia-ALL-during-the-62nd-ASH-Annual-Meeting.html 19. “Committee for Advanced Therapies (CAT): 2-4 December 2020” EMA. Accessed Dec. 22, 2020 Available from: https://www.ema.europa.eu/en/events/committee-advanced-therapies-cat-2-4-december-2020 20. “Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020” EMA. Accessed Dec.11,2020 Available from: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020 21. “Libmeldy” EMA. Accessed Dec.22,2020 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy 22. “What’s new” EMA. Accessed Dec. 2020 Available from: https://www.ema.europa.eu/en/news-events/whats-new/2020-12 23. “YESCARTA approved in Japan for treatment of patients with relapsed/refractory large B-cell lymphoma”. News release (January 22, 2021). Daiichi-Sankyo. Accessed January 25, 2021. Available from: http://bit.ly/2Y4qc0R. 24. 정우용 기자. “면역세포치료제 '예스카타' 日 신청재발 또는 난치성 B세포림프종 대상” , (의학신문(2020.04.01.) Available from: http://www.bosa.co.kr/news/articleView.html?idxno=2124384 25. 통계청. 사망원인통계결과. 2019 Available from: http://kostat.go.kr/portal/korea/kor_nw/1/6/2/index.board?bmode=read&bSeq=&aSeq=385219&pageNo=1&rowNum=10&navCount=10&currPg=&searchInfo=&sTarget=title&sTxt= 26. 식품의약품안전평가원. CAR-T 세포면역항암치료제 연구개발 및 규제동향. 2020. Available from: https://www.nifds.go.kr/brd/m_18/view.do?seq=12530 27. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar; 17(3):147-167 28. Stock S, Schimitt M, Sellner L. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci. 2019 Dec 10; 20(24):6223 29. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018 Feb 1;378(5):439-448 30. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019 Jan 3;380(1):45-56. 31. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017 Dec 28;377(26):2531-2544. 32. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020 Apr 2;382(14):1331-1342 33. 식품의약품안전평가원. 면역조절 세포치료제 연구개발 동향. 2016 Available from: https://www.mfds.go.kr/brd/m_386/view.do?seq=23520 34. CH June, et al. CAR T cell immunotherapy for human cancer. Science 2018 Mar 23; 359(6382):1361-1365. 35. Siegler EL, Kenderian SS. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol 2020 Aug 28; 11:1973
|